The Prevention of Postmenopausal Osteoporotic Fractures: Results of the Health Technology Assessment of a New Antiosteoporotic Drug

Table 3

Number of fractures occurring in patients given different treatments and pertaining costs.

	2010	2011	2012	2013
Hip/femoral fractures (alternatives)	36,343	37,142	37,971	38,657
Hip/femoral fractures (denosumab)	36,343	37,049	37,808	38,382
Hip/femoral fractures avoided with denosumab	—	93	163	275
Saving (€)	—	860,000	2,042,000	3,788,000
Vertebral fractures (alternatives)	21,487	21,506	21,612	21,640
Vertebral fractures (denosumab)	21,487	21,370	21,387	21,268
Vertebral fractures avoided with denosumab	—	136	225	372
Saving (€)	—	333,000	653,000	1,139,000